Success Metrics

Clinical Success Rate
77.8%

Based on 7 completed trials

Completion Rate
78%(7/9)
Active Trials
1(8%)
Results Posted
57%(4 trials)
Terminated
2(17%)

Phase Distribution

Ph phase_3
3
25%
Ph phase_1
4
33%
Ph not_applicable
2
17%
Ph phase_2
3
25%

Phase Distribution

4

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
4(33.3%)
Phase 2Efficacy & side effects
3(25.0%)
Phase 3Large-scale testing
3(25.0%)
N/ANon-phased studies
2(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

1

trials recruiting

Total Trials

12

all time

Status Distribution
Active(1)
Completed(7)
Terminated(2)
Other(2)

Detailed Status

Completed7
unknown2
Terminated2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
1
Success Rate
77.8%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (33.3%)
Phase 23 (25.0%)
Phase 33 (25.0%)
N/A2 (16.7%)

Trials by Status

unknown217%
completed758%
recruiting18%
terminated217%

Recent Activity

1 active trials
Showing 5 of 12
recruitingnot_applicable

Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

NCT03223922
completedphase_2

Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain

NCT03898908
completedphase_3

Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases

NCT02360215
unknownphase_2

Radiotherapy of Multiple Brain Metastases Using AGuIX®

NCT03818386
terminatedphase_1

A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy

NCT03608020
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT03223922Not Applicable

Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

Recruiting
NCT03898908Phase 2

Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain

Completed
NCT02360215Phase 3

Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases

Completed
NCT03818386Phase 2

Radiotherapy of Multiple Brain Metastases Using AGuIX®

Unknown
NCT03608020Phase 1

A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy

Terminated
NCT02953717Not Applicable

Cognitive Outcome After SRS or WBRT in Patients With Multiple Brain Metastases (CAR-Study B)

Unknown
NCT00548756Phase 3

Randomized Trial Comparing Radiosurgery With vs Without Whole Brain Radiotherapy

Completed
NCT02820454Phase 1

Radiosensitization of Multiple Brain Metastases Using AGuIX Gadolinium Based Nanoparticles

Completed
NCT01657799Phase 2

Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer

Completed
NCT00649207Phase 1

A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases

Completed
NCT00566852Phase 3

Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors

Completed
NCT00437957Phase 1

Phase I Study of Temozolomide, Valproic Acid and Radiation Therapy in Patients With Brain Metastases

Terminated

All 12 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
12